One ASX company Set to Revolutionise the $112 BILLION Cancer-Drug Market
By: Adam Surplice
Industry experts expect that the total market for cancer drugs will top $112 billion by 2020.
That's why we're so excited about one small ASX biotech company—and its revolutionary new technology, which could change the way cancer drugs are administered, both here in Australia and all around the world.
Even though this company is still "early stage" it has one product in the market and multiple products in its pipeline, and is approaching profitability at lightning speed.
Then there's the additional $1 billion market it has just cracked in China and Japan.
And finally the cherry on top — the company's one of a kind biotechnology, protected by over 100 patents and highly sought after by the world's biggest healthcare and pharmaceutical companies.
This singular and utterly unique nanoscale technology stands to change the way cancer is treated. It could even help to effect a cure.
Global drug giants are already lining up for access to this innovative technology—inking lucrative multi-year deals which have brought cash pouring in.
Now you see why we're so excited about this ASX biotech. Particularly the investment potential for shareholders. Cancer-Drug Market
If everything goes to plan, early investors could see as much as 10X returns from here, as the company begins to reach its vast total addressable market (due to be worth $112 billion by 2020!).
When you look at the history of the truly ground-breaking ASX medical technology stocks, the potential looks even greater…
Consider the returns of CSL, ResMed and Cochlear over the last 20 years.
If you'd invested just $10,000 into each of those stocks in 1995, you'd be sitting on more than $3.2 MILLION right now.
To me, the evidence looks overwhelming—this ASX biotech could be set to soar. But you're going to want to size up this research for yourself as soon as possible.
How to access this brand-new report on the stock experts think could be the next Cochlear… the next CSL… the next ResMed…
Many investors treat biotech stocks like a roulette wheel… plunking down their hard-earned cash on random shares they heard about from a mate or read about on a chat forum…
With no clue that they're actually in line to lose everything… or that there's a far better way to play the game.
But a small handful of in-the-know investors could likely get filthy rich from truly being on the ground floor of the age of this exciting new biotech development.
Enter your email address below to learn more now – including how you can secure your copy of this brand new report, One Small ASX Biotech That Could Utterly Transform Cancer Treatment!
Timing isn't everything, but history has shown that it has paid to get in early on these enormous investing trends.
Investors who waited to get in on CSL, Cochlear or ResMed might have done okay… but they missed the truly life-changing early returns.
And though this smaller ASX biotech stock is already up a stunning 515% since its float in 2009, our team is convinced the big gains could be just beginning.
Forget penny pot stocks.
Forget fly-by-night operators who may (or may not) have a viable business plan.
THIS is the company we think you should have in your portfolio if you want to position yourself wisely for the coming $112 billion boom.
Because even though this company has had unprecedented success so far, fewer investors than you might expect are taking advantage of this VERY rare opportunity…
That's where our brand-new report One Small ASX Biotech That Could Utterly Transform Cancer Treatment comes in.
It reveals the reasons why we think every forward-thinking investor should be paying close attention to this revolutionary new biotechnology and what could be its life-changing investment potential.
This report is FREE to you when you sign up for Extreme Opportunities today.
Simply enter your email address below to learn about the one biotech stock we think you need in your portfolio.
ENTER YOUR EMAIL ADDRESS TO DISCOVER MORE NOW
This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. For more information about The Motley Fool see our Financial Services Guide. All returns cited are hypothetical and based on the percentage change between the stock price at the time of recommendation and the current or sell price (if the position has been closed) at the time of publication. Brokerage, taxes and any other associated costs are not taken into account. Please remember that investments can go up and down. Past performance is not necessarily indicative of future returns. Performance figures are not intended to be a forecast and The Motley Fool does not guarantee the performance of, or returns on any investment. Any money back guarantee is strictly limited to the subscription price paid for the product.